Menu
← Oncology Approval Tracker
FDA DECISION ·
Turalio
pexidartinib · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
A revised 125 mg capsule and recommended 250 mg twice-daily regimen with a low-fat meal for adults with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitation and unsuitable for improvement with surgery.
LAMPGEN ANALYSIS
Why it matters
The new strength and food instructions change how patients take pexidartinib.
What research teams should watch
Reconcile capsule strength and meal instructions at dispensing and maintain liver safety monitoring and REMS documentation.
PRIMARY RECORDS